"Continue to See Vtama’s Profile as Truly Differentiated" - Truist Securities Bullish on Roivant Sciences (ROIV) with $15 Price Target

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $15.00 price target on Roivant Sciences (NASDAQ: ROIV), following FDA approval of the company's Vtama cream.

The analyst comments: "We think the pricing and launch strategy could secure on-formulary and plan reimbursement sooner than expected. We model minimal 2022 Vtama revenue due to near-term extensive discounting/free drug and expect meaningful sales to come as payer contracts are finalized over the next 12-18mo. While Vtama WAC $1,325/tube is in-line with estimates, uncertainty remains in real-world use of tubes/year (see below) and will become clearer as launch progresses. We continue to see Vtama’s profile as truly differentiated in plaque psoriasis and potentially related indications. Reiterate Buy and $15 PT."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $3.91 yesterday.

By Vlad Schepkov

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Invesco (IVZ) PT Lowered to $16 at RBC Capital
• Boston Scientific (BSX) PT Raised to $84 at Baird